EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

T lymphocyte–specific deletion of SHP1 and SHP2 promotes activation-induced cell death of CD4 + T cells and impairs antitumor response

Connor J R Foster, Jasper Du iD, Oscar Pundel, Mitchell J Geer, Ryan C Ripert, Jia Liu iD, Taylor A Heim, Kiyomi Y Araki, Amanda W Lund, Jun Wang iD, Benjamin G Neel iD

Proceedings of the National Academy of Sciences · 2025

DOI: 10.1073/pnas.2427254122 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2025. Verfasst von Connor J R Foster und 10 weiteren Autor:innen. Beteiligte Einrichtung: The Laura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, NY 10016. Hauptthemen laut MEDLINE: Protein Tyrosine Phosphatase, Non-Receptor Type 11, Protein Tyrosine Phosphatase, Non-Receptor Type 6, CD4-Positive T-Lymphocytes. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAMS NIH HHS, NIGMS NIH HHS, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

SHP1 (PTPN6) and SHP2 (PTPN11) are closely related protein-tyrosine phosphatases (PTPs), which are autoinhibited until their SH2 domains bind paired tyrosine-phosphorylated immunoreceptor tyrosine-based inhibitory/switch motifs (ITIMs/ITSMs). These PTPs bind overlapping sets of ITIM/ITSM-bearing proteins, suggesting that they might have some redundant functions. By studying T cell–specific single and double knockout mice, we found that SHP1 and SHP2 redundantly restrain naïve T cell differentiation to effector and central memory phenotypes, with SHP1 playing the dominant role. Surprisingly, loss of SHP2 alone in T cells enhanced the antitumor effects of anti-PD-1 antibodies, whereas there was no effect of SHP1 deletion. Also unexpectedly, the absence of both PTPs resulted in poorer tumor control and failure to respond to Programmed Cell Death Protein 1 (PD-1) blockade, associated with reduced frequency and activation of T cells and dendritic cells. Mechanistic studies revealed that CD4 + , but not CD8 + , T cells lacking SHP1 and SHP2 show increased activation-induced cell death upon anti-CD3/CD28 stimulation. Adoptive transfer of antigen-specific CD4 + T cells restored normal levels of tumor control in mice lacking both PTPs. Together, our results demonstrate that SHP1 or SHP2 is required to prevent activation-induced cell death of CD4 + T cells and is critical for tumor immunity, raising the possibility that inhibition of SHP2 might augment the therapeutic efficacy of PD-1-based immune therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Tyrosine Phosphatase, Non-Receptor Type 11Protein Tyrosine Phosphatase, Non-Receptor Type 6CD4-Positive T-LymphocytesAnimalsMiceMice, KnockoutProgrammed Cell Death 1 ReceptorLymphocyte ActivationCell DeathMice, Inbred C57BL

Stichwörter der Autor:innen

ITIMPD-1PTPN11PTPN6tumor immunity

Substanzen

Protein Tyrosine Phosphatase, Non-Receptor Type 11Protein Tyrosine Phosphatase, Non-Receptor Type 6Ptpn11 protein, mousePtpn6 protein, mouseProgrammed Cell Death 1 ReceptorPdcd1 protein, mouse

Autor:innen und Institutionen

  • The Laura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, NY 10016.
  • Department of Pathology, New York University Grossman School of Medicine, New York, NY 10016.
  • Department of Dermatology, New York University Grossman School of Medicine, New York, NY 10016.

ORCID-Profile: Jasper Du, Jia Liu, Jun Wang, Benjamin G Neel

Förderung

  • NIAMS NIH HHS
  • NIGMS NIH HHS
  • NIAID NIH HHS
  • HHS | NIH | National Cancer Institute (NCI)
  • NCI NIH HHS
  • HHS | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
  • Melanoma Research Alliance (MRA)
  • HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID)

Zitieren

APA

Foster, C. J. R., Du, J., Pundel, O., Geer, M. J., Ripert, R. C., Liu, J., Heim, T. A., Araki, K. Y., Lund, A. W., Wang, J., & Neel, B. G. (2025). T lymphocyte–specific deletion of SHP1 and SHP2 promotes activation-induced cell death of CD4 + T cells and impairs antitumor response. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2427254122

Vancouver

Foster CJR, Du J, Pundel O, Geer MJ, Ripert RC, Liu J, et al. T lymphocyte–specific deletion of SHP1 and SHP2 promotes activation-induced cell death of CD4 + T cells and impairs antitumor response. Proceedings of the National Academy of Sciences. 2025. doi:10.1073/pnas.2427254122

BibTeX
@article{Foster2025,
  author = {Foster, Connor J R and Du, Jasper and Pundel, Oscar and Geer, Mitchell J and Ripert, Ryan C and Liu, Jia and Heim, Taylor A and Araki, Kiyomi Y and Lund, Amanda W and Wang, Jun and Neel, Benjamin G},
  title = {T lymphocyte–specific deletion of SHP1 and SHP2 promotes activation-induced cell death of CD4 + T cells and impairs antitumor response},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2025},
  doi = {10.1073/pnas.2427254122}
}
Kostenlos starten →